$1.74
-0.08 (-4.40%)
Open$1.79
Previous Close$1.82
Day High$1.83
Day Low$1.72
52W High$64.12
52W Low$1.36
Volume—
Avg Volume41.2K
Market Cap4.11M
P/E Ratio—
EPS$-51.65
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+2,163.8% upside
Current
$1.74
$1.74
Target
$39.39
$39.39
$26.66
$39.39 avg
$54.88
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.03M | 1.06M | 807.5K |
| Net Income | -278,352 | -347,095 | -248,556 |
| Profit Margin | -27.1% | -32.7% | -30.8% |
| EBITDA | -433,012 | -468,823 | -342,942 |
| Free Cash Flow | -135,403 | -181,532 | -119,491 |
| Rev Growth | +14.1% | -2.0% | +8.2% |
| Debt/Equity | 0.22 | 0.23 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |